{
    "clinical_study": {
        "@rank": "127890", 
        "arm_group": [
            {
                "arm_group_label": "vitamin c", 
                "arm_group_type": "Active Comparator", 
                "description": "25  heavily iron-loaded thalassemia patients, receiving adjuvant vitamin c with iron chelator."
            }, 
            {
                "arm_group_label": "iron chelator", 
                "arm_group_type": "Other", 
                "description": "Included 25  heavily iron-loaded thalassemia patients,  not receiving adjuvant vitamin c with iron chelator."
            }
        ], 
        "brief_summary": {
            "textblock": "role of Vit C to Augment iron chelation with DFP or DFX in thalassemic patients."
        }, 
        "brief_title": "Role of Vitamin C to Augment Iron Chelation With DFP or DFX", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Vitamin c", 
            "Thalassemia Major", 
            "Iron Chelation"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Beta-Thalassemia", 
                "Thalassemia"
            ]
        }, 
        "detailed_description": {
            "textblock": "assess safety and   efficacy of Vit C to Augment iron chelation with DFP or DFX in\n      thalassemic patients."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  \u2022 Subjects with overload secondary to thalassemia major\n\n        Exclusion Criteria:\n\n          -  \u2022 with HIV positive or have active HCV.\n\n               -  A history of serious immunologic hypersensitivity to any medication such as\n                  anaphylaxis or angioedema.\n\n               -  Participation in a previous investigational drug study within the 30 days\n                  preceding screening.\n\n               -  A woman of childbearing potential must have a negative serum pregnancy test at\n                  screening. She must use a medically acceptable form of birth control during the\n                  study and for a month afterwards who are pregnant or breast-feeding.\n\n               -  An inability to adhere to the designated procedures and restrictions of this\n                  protocol."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "6 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02083575", 
            "org_study_id": "vitamin c and iron chelator"
        }, 
        "intervention": [
            {
                "arm_group_label": "vitamin c", 
                "description": "adjuvant vitamin c with iron chelator.", 
                "intervention_name": "Vitamin C, Defriprone, deferisarox", 
                "intervention_type": "Drug", 
                "other_name": [
                    "vitamin c", 
                    "DFP", 
                    "DFX"
                ]
            }, 
            {
                "arm_group_label": "iron chelator", 
                "description": "iron chelator", 
                "intervention_name": "deferiprone , deferesarox", 
                "intervention_type": "Drug", 
                "other_name": [
                    "DFP", 
                    "DFX"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Ascorbic Acid", 
                "Vitamins", 
                "Iron", 
                "Chelating Agents", 
                "Deferiprone"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "vitamin c", 
            "thalassemia major", 
            "iron chelation"
        ], 
        "lastchanged_date": "March 7, 2014", 
        "location": {
            "contact": {
                "email": "AMIRADIABETES@YAHOO.COM", 
                "last_name": "MOHSEN S ELALFY, PROF"
            }, 
            "facility": {
                "address": {
                    "city": "Cairo,", 
                    "country": "Egypt"
                }, 
                "name": "Pediatric Hematology clinic, Ain Shams University Egypt"
            }, 
            "investigator": {
                "last_name": "MOHSEN S ELALFY, PROF", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Egypt"
        }, 
        "number_of_arms": "2", 
        "official_title": "Study of Safty and Efficacy of Adjuvant Vitamin c in Augmenting Iron Chelation", 
        "overall_contact": {
            "email": "AMIRADIABETES@YAHOO.COM", 
            "last_name": "MOHSEN S ELALFY, PROF."
        }, 
        "overall_official": {
            "affiliation": "Ain Shams University", 
            "last_name": "MOHSEN S ELALFY, PROF.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Egypt: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "assess safety and   efficacy of Vit C to Augment iron chelation with DFP or DFX in thalassemic patients.", 
                "measure": "Vit C to Augment iron chelation", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "better reduction in serum ferritin, LIC and cardiac T28 in group receiving vitamin c", 
                "measure": "vitamin c augmenting effect of iron chelator", 
                "safety_issue": "No", 
                "time_frame": "12 month"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02083575"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Ain Shams University", 
            "investigator_full_name": "Mohsen Saleh Elalfy", 
            "investigator_title": "professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "safety and occurrence of AEs in both studied groups", 
            "measure": "adverse related events", 
            "safety_issue": "No", 
            "time_frame": "12 month"
        }, 
        "source": "Ain Shams University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ain Shams University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}